Search

Your search keyword '"Goncalves, Trecy"' showing total 16 results
Start Over Author "Goncalves, Trecy"
16 results on '"Goncalves, Trecy"'

1. Left atrioventricular coupling index assessed using cardiac CT as a prognostic marker of cardiovascular death

Author

Pezel, Théo, Dillinger, Jean-Guillaume, Toupin, Solenn, Mirailles, Raphael, Logeart, Damien, Cohen-Solal, Alain, Unger, Alexandre, Canuti, Elena Sofia, Beauvais, Florence, Lafont, Alexandre, Gonçalves, Trecy, Lequipar, Antoine, Gall, Emmanuel, Boutigny, Alexandre, Ah-Sing, Tania, Hamzi, Lounis, Lima, Joao A.C., Bousson, Valérie, and Henry, Patrick

Published
2023
Full Text
View/download PDF

3. Assessment of the routine reporting of very low-dose exercise-first myocardial perfusion SPECT from a large-scale real-world cohort and correlation with the subsequent reporting of coronary stenosis at angiography

Author

Chawki, Mohammad B., Goncalves, Trecy, Boursier, Caroline, Bordonne, Manon, Verger, Antoine, Imbert, Laetitia, Perrin, Mathieu, Claudin, Marine, Roch, Véronique, Djaballah, Karim, Popovic, Batric, Camenzind, Edoardo, and Marie, Pierre-Yves

Published
2022
Full Text
View/download PDF

6. Kiosk 10R-TB-03 - Supervised Machine-learning Model Using Multimodality Imaging for Prediction of Cardiovascular Events in Patients with Obstructive CAD

Author

Pezel, Theo, Toupin, Solenn, Bousson, Valérie, Hamzi, Kenza, Hovasse, Thomas, Lefevre, Thierry, Chevalier, Bernard, Unterseeh, Thierry, Sanguineti, Francesca, Champagne, Stephane, Benamer, Hakim, Neylon, Antoinette, Akodad, Mariama, Ah-Sing, Tania, Hamzi, Lounis, Gonçalves, Trecy, Lequipar, Antoine, Gall, Emmanuel, Unger, Alexandre, Dillinger, Jean Guillaume, Henry, Patrick, Garot, Philippe, and Garot, Jérome

Published
2024
Full Text
View/download PDF

9. CMR 2-76 - Prognostic Impact of the Extent, Location, and Pattern of Late Gadolinium Enhancement (LGE) in Dilated Cardiomyopathy (DCM) and Isolated Left Ventricular Dilation Patients

Author

Gonçalves, Trecy, Pezel, Theo, Garot, Philippe, Unterseeh, Thierry, Hovasse, Thomas, Toupin, Solenn, Champagne, Stéphane, Ah-Sing, Tania, Hamzi, Lounis, Unger, Alexandre, Dillinger, Jean Guillaume, Henry, Patrick, Sanguineti, Francesca, Bousson, Valérie, and Garot, Jérome

Published
2024
Full Text
View/download PDF

12. Assessment of the routine reporting of very low-dose exercise-first myocardial perfusion SPECT from a large-scale real-world cohort and correlation with the subsequent reporting of coronary stenosis at angiography

Author

Chawki, Mohammad B., primary, Goncalves, Trecy, additional, Boursier, Caroline, additional, Bordonne, Manon, additional, Verger, Antoine, additional, Imbert, Laetitia, additional, Perrin, Mathieu, additional, Claudin, Marine, additional, Roch, Véronique, additional, Djaballah, Karim, additional, Popovic, Batric, additional, Camenzind, Edoardo, additional, and Marie, Pierre-Yves, additional

Published
2021
Full Text
View/download PDF

13. Ischemia Is an Efficient Predictor of Significant Coronary Artery Disease in Routine Reports of a Large-scale Clinical Cohort Using Very Low-dose Exercise-first Myocardial Perfusion SPECT

Author

Chawki, Mohammad Bilal, primary, Goncalves, Trecy, additional, Boursier, Caroline, additional, Bordonne, Manon, additional, Verger, Antoine, additional, Imbert, Laetitia, additional, Perrin, Mathieu, additional, Claudin, Marine, additional, Roch, Veronique, additional, Djaballah, Karim, additional, Popovic, Batric, additional, Camenzind, Edoardo, additional, and Marie, Pierre-Yves, additional

Published
2021
Full Text
View/download PDF

14. Effets indésirables cardiovasculaires sous inhibiteurs de la Bruton tyrosine kinase : mécanismes physiopathologiques, dépistage et prise en charge

Author

Cautela, Jennifer, Croizier, Carolyne, Inchiappa, Luca, Goncalves, Trecy, Stocker, Nicolas, and Tchernonog, Emmanuelle

Abstract

Les inhibiteurs covalents de la Bruton tyrosine kinase (iBTK) ont profondément transformé la prise en charge des hémopathies lymphoïdes B, en particulier la leucémie lymphoïde chronique. Ces thérapies ciblées, dont l’ibrutinib est le pionnier, ont ouvert la voie à une amélioration significative du pronostic de nombreux patients. Avec les iBTK de seconde génération, tels que l’acalabrutinib et le zanubrutinib, la palette thérapeutique s’est élargie, présentant de potentielles nouvelles options pour les patients atteints de leucémie lymphoïde chronique. Cet article de synthèse se concentre sur les effets indésirables cardiovasculaires associés à ces traitements. Il explore en détail les mécanismes physiopathologiques sous-jacents à ces effets, mettant en lumière les interactions complexes entre ces molécules et le système cardiovasculaire. En outre, il examine la fréquence des effets indésirables selon le type d’iBTK, en s’appuyant sur des données issues d’études cliniques et de la pratique clinique réelle. Enfin, l’importance d’une surveillance cardio-oncologique étroite est soulignée, avec une collaboration essentielle entre hématologues et cardiologues. Des stratégies de dépistage et de prise en charge des effets indésirables cardiovasculaires sont également discutées, mettant en avant la nécessité d’une approche proactive dans la gestion de ces complications. Les experts proposent un suivi pragmatique de ces patients, à travers des figures récapitulatives, adaptées des recommandations européennes de cardio-oncologie, pour simplifier la pratique des hématologues.

Published
2024
Full Text
View/download PDF

15. [Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: Pathophysiological mechanisms, screening, and management].

Author

Cautela J, Croizier C, Inchiappa L, Goncalves T, Stocker N, and Tchernonog E

Abstract

The covalent Bruton tyrosine kinase inhibitors (iBTKs) have profoundly transformed the management of B-cell lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). These targeted therapies, with ibrutinib as the pioneer, have paved the way for significant improvement in the prognosis of many patients. With second-generation iBTKs such as acalabrutinib and zanubrutinib, the therapeutic landscape has expanded, offering potential new options for patients with CLL. This review focuses on the cardiovascular adverse effects associated with these treatments. It delves into the underlying pathophysiological mechanisms of these effects, highlighting the complex interactions between these molecules and the cardiovascular system. Additionally, it examines the frequency of adverse effects according to the type of iBTK, drawing on data from clinical trials and real-world clinical practice. Finally, the importance of close cardio-oncological monitoring is emphasized, with essential collaboration between hematologists and cardiologists. Strategies for screening and managing cardiovascular adverse effects are also discussed, emphasizing the need for a proactive approach in managing these complications. Experts propose a pragmatic follow-up of these patients, through a central illustration and a figure adapted from European cardio-oncology guidelines, to simplify hematologists' practice., (Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2024
Full Text
View/download PDF

16. [Recreative drug use and cardiovascular disease].

Author

Clement A, Pezel T, Lequipar A, Guiraud-Chaumeil P, Singh M, Poinsignon H, El Beze N, Gall E, Goncalves T, Lafont A, Henry P, and Dillinger JG

Abstract

Widely spread, and continuously increasing, recreational drug use in general population has been associated with cardiovascular events, as illustrated by clinical studies and supported by a pathophysiological rationale. Understanding the cardiovascular effects of drugs, screening, and secondary prevention are crucial components in the management of those patients in cardiology., Competing Interests: Déclaration de liens d'intérêts Les auteurs déclarent n'avoir aucun lien d'intérêt., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results